MRK - Merck Stock

Market Summary

USD107.31-0.05

Market Closed

-0.05%

MRK Alerts

1 major insider sales recently.
Big fall in earnings (Y/Y)
Losses in recent quarter

MRK Stock Price

MRK RSI Chart

MRK Valuation

Market Cap

272.8B

Price/Earnings (Trailing)

17.88

Price/Sales (Trailing)

4.63

EV/EBITDA

14

Price/Free Cashflow

13.8

MRK Price/Sales (Trailing)

MRK Profitability

EBT Margin

26.32%

Return on Equity

27.82%

Return on Assets

12.09%

Free Cashflow Yield

7.24%

MRK Fundamentals

MRK Revenue

Revenue (TTM)

58.3B

Revenue Y/Y

3.03%

Revenue Q/Q

3.78%

MRK Earnings

Earnings (TTM)

3.1B

Earnings Y/Y

-251.5%

Earnings Q/Q

-311.8%

Price Action

52 Week Range

83.38119.65

(Low)(High)

Last 7 days

0.2%

Last 30 days

-2.1%

Last 90 days

-5.6%

Trailing 12 Months

26.5%

MRK Financial Health

Current Ratio

1.44

MRK Investor Care

Dividend Yield

2.64%

Dividend/Share (TTM)

2.8

Diluted EPS (TTM)

1.22

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for MRK

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-08-14	MIZELL STEVEN	sold	-463,292	109	-4,250	evp, chief hr officer
2023-08-03	Guindo Chirfi	acquired	3,900,440	105	36,901	chief marketing officer
2023-08-03	Guindo Chirfi	sold (taxes)	-1,901,440	105	-17,989	chief marketing officer
2023-08-03	MIZELL STEVEN	sold	-474,701	105	-4,500	evp, chief hr officer
2023-08-02	Romanelli Joseph	sold	-6,334	107	-59.00	president, human health int?l
2023-08-02	Romanelli Joseph	sold	-3,221	107	-30.00	president, human health int?l
2023-05-04	LeCointe-Cephas Lisa	sold (taxes)	-32,983	118	-279	svp chief ethics & com officer
2023-05-04	Oosthuizen Johannes Jacobus	sold (taxes)	-52,844	118	-447	president, u.s. market
2023-05-04	Zachary Jennifer	sold	-2,250,830	117	-19,141	evp, general counsel
2023-05-04	Oosthuizen Johannes Jacobus	acquired	107,226	118	907	president, u.s. market

Which funds bought or sold MRK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-09-19	BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL	reduced	-17.22	-536,100	4,711,370	1.97%
2023-09-18	WASHINGTON CAPITAL MANAGEMENT, INC	unchanged	-	140,022	1,795,240	1.53%
2023-09-18	CAPE ANN SAVINGS BANK	added	13.19	268,635	1,448,610	0.96%
2023-09-14	IMS Capital Management	reduced	-1.45	97,589	1,514,500	0.84%
2023-09-13	CGC Financial Services, LLC	new	-	173,132	173,132	0.11%
2023-09-12	Prosperity Wealth Management, Inc.	new	-	211,048	211,048	0.14%
2023-09-12	Prosperity Financial Group, Inc.	added	2.91	40,392	388,287	0.34%
2023-09-12	Farther Finance Advisors, LLC	added	10.48	101,691	614,461	0.13%
2023-09-12	DCM Advisors, LLC	reduced	-15.68	-88,626	948,889	0.41%
2023-09-11	BLUEFIN CAPITAL MANAGEMENT, LLC	new	-	426,943	426,943	0.08%

Latest Funds Activity

Are funds buying MRK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MRK

No. of Funds

Schedule 13G FIlings of Merck

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	vanguard group inc	8.96%	227,205,978	SC 13G/A
Feb 03, 2023	blackrock inc.	8.5%	215,011,385	SC 13G/A
Feb 09, 2022	vanguard group inc	8.36%	211,202,531	SC 13G/A
Feb 01, 2022	blackrock inc.	7.8%	198,224,264	SC 13G/A
Feb 10, 2021	vanguard group inc	8.24%	208,410,644	SC 13G/A
Feb 05, 2021	blackrock inc.	7.8%	196,213,804	SC 13G/A
Feb 12, 2020	vanguard group inc	8.26%	210,542,333	SC 13G/A
Feb 05, 2020	blackrock inc.	7.5%	190,783,225	SC 13G/A

Recent SEC filings of Merck

View All Filings

Date Filed	Form Type	Document
Aug 15, 2023	4	Insider Trading
Aug 14, 2023	144	Notice of Insider Sale Intent
Aug 07, 2023	10-Q	Quarterly Report
Aug 04, 2023	4	Insider Trading
Aug 04, 2023	4	Insider Trading
Aug 03, 2023	4	Insider Trading
Aug 03, 2023	144	Notice of Insider Sale Intent
Aug 01, 2023	8-K	Current Report
Jul 05, 2023	4	Insider Trading
Jul 05, 2023	4	Insider Trading

Peers (Alternatives to Merck)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
LLY	512.5B	29.5B	3.56%	89.32%	78.88	17.36	1.53%	14.16%
JNJ	423.3B	97.8B	-2.65%	0.10%	32.43	4.33	2.29%	-28.92%
MRK	272.8B	58.3B	-2.13%	26.48%	17.88	4.63	2.00%	-81.24%
PFE	189.8B	77.9B	-9.16%	-24.26%	8.84	2.44	-23.04%	-26.74%
BMY	150.1B	45.2B	-5.06%	-15.06%	23.72	3.25	-4.15%	20.34%
MID-CAP
RETA	6.5B	-	1.75%	544.26%	-74.04	4.1K	-86.94%	71.24%
PRGO	4.5B	4.6B	-11.49%	-16.32%	-66.69	0.98	6.60%	42.04%
SMALL-CAP
TLRY	1.9B	627.1M	-7.75%	-1.79%	-1.34	3.1	-0.20%	-204.67%
SUPN	1.5B	634.0M	-11.88%	-19.94%	34.62	2.37	0.62%	-24.59%
INVA	832.3M	244.3M	-4.13%	4.68%	4.22	3.41	-39.50%	-4.99%
CRON	830.8M	109.5M	21.79%	-27.57%	-5.79	7.59	-2.66%	-32.13%
CGC	480.0M	453.3M	110.37%	-71.69%	-0.39	1.06	-16.04%	55.90%
ACRS	479.1M	31.2M	-7.77%	-52.62%	-4.55	15.37	407.54%	-26.47%
OCUL	269.4M	54.6M	-13.04%	-44.44%	-2.97	4.93	9.39%	-179.16%
ENDP	-	2.2B	-	-	-	-	-22.39%	63.59%

Merck News

Returns for MRK

Cumulative Returns on MRK

12.2%

10-Year Cumulative Returns

11.9%

7-Year Cumulative Returns

12.7%

5-Year Cumulative Returns

12.4%

3-Year Cumulative Returns

Risks for MRK

What is the probability of a big loss on MRK?

16.5%

Probability that Merck stock will be more than 20% underwater in next one year

0%

Probability that Merck stock will be more than 30% underwater in next one year.

0%

Probability that Merck stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does MRK drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Merck was unfortunately bought at previous high price.

Drawdowns

Financials for Merck

Income Statement (Last 12 Months)
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	0.8%	58,311	57,869	59,283	58,974	57,169	53,978	48,704	46,131	43,906	41,857	41,518	36,488	37,956	40,363	39,121	45,971	44,368	43,073	42,294	41,729	41,260
S&GA Expenses	1.9%	10,388	10,198	10,042	10,185	10,001	9,770	9,634	9,423	9,147	8,951	8,955	8,429	8,958	9,585	9,455	10,369	10,223	10,019	10,102	10,101	10,117
R&D Expenses	69.0%	25,771	15,248	13,548	12,841	10,887	12,410	12,245	14,966	15,870	13,634	13,397	10,043	9,898	10,002	9,724	9,538	8,402	8,487	9,752	9,853	12,198
EBITDA	-100.0%	-	17,060	18,244	18,664	21,157	18,246	16,285	11,760	9,660	14,490	13,279	13,005	11,945	12,412	11,716	-	-	-	-	-	-
EBITDA Margin	-100.0%	-	0.29*	0.31*	0.32*	0.37*	0.34*	0.33*	0.28*	0.23*	0.28*	0.28*	0.34*	0.31*	0.31*	0.30*	-	-	-	-	-	-
Earnings Before Taxes	-64.5%	5,411	15,233	16,444	16,840	18,523	15,753	13,879	7,425	4,865	5,889	5,863	7,783	7,424	7,942	7,171	11,277	11,595	10,422	8,701	7,975	5,510
EBT Margin	-100.0%	-	0.26*	0.28*	0.29*	0.32*	0.29*	0.28*	0.25*	0.20*	0.19*	0.18*	0.22*	0.20*	0.20*	0.18*	-	-	-	-	-	-
Net Income	-76.1%	3,111	13,030	14,519	15,260	16,579	14,180	13,049	7,197	5,571	7,028	7,067	11,518	10,478	10,146	9,843	9,313	9,362	8,399	6,220	3,347	1,341
Net Income Margin	-100.0%	-	0.23*	0.24*	0.26*	0.29*	0.26*	0.27*	0.17*	0.13*	0.14*	0.15*	0.30*	0.28*	0.25*	0.25*	-	-	-	-	-	-
Free Cashflow	-100.0%	-	15,673	19,095	19,760	18,955	16,092	13,122	12,033	9,409	11,337	10,253	11,041	13,094	12,811	13,440	-	-	-	-	-	-

Balance Sheet
(In Millions)

Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Assets	-3.1%	104,469	107,796	109,160	107,081	107,095	106,668	105,694	93,494	90,688	90,847	91,588	89,800	90,615	84,913	84,397	83,331	83,965	82,354	82,637	85,130	85,040
Current Assets	-10.3%	29,977	33,402	35,722	33,561	32,116	31,184	30,266	31,058	28,665	26,909	27,764	26,577	29,343	26,174	27,483	26,142	24,298	25,351	25,875	26,836	24,064
Cash Equivalents	-41.7%	5,660	9,707	12,694	11,145	9,753	8,614	8,167	10,046	8,630	6,882	8,153	7,401	11,147	7,460	9,934	7,871	6,660	8,077	7,967	7,828	5,312
Inventory	1.1%	5,930	5,863	5,911	5,614	5,535	5,774	5,953	5,603	5,499	6,402	5,554	6,128	6,056	5,846	5,978	5,855	5,847	5,712	5,440	5,416	5,178
Net PPE	2.2%	22,231	21,758	21,422	20,424	20,059	19,747	19,279	18,565	18,064	18,295	17,000	16,919	15,789	15,269	14,297	14,287	13,862	13,506	13,291	12,755	12,626
Goodwill	-0.1%	21,195	21,209	21,204	21,160	21,213	21,258	21,264	18,862	18,873	20,212	18,882	20,248	239	19,767	18,069	19,480	19,490	1,376	18,253	18,258	18,274
Current Liabilities	1.1%	23,394	23,131	24,239	22,998	23,168	22,316	23,872	23,728	21,906	26,361	27,327	20,405	22,178	23,483	22,220	20,684	20,085	18,543	22,206	18,586	18,128
LT Debt, Non Current	21.4%	34,072	28,074	28,745	28,482	28,684	30,586	30,690	22,907	24,033	24,002	25,360	26,321	26,156	21,637	22,736	22,677	22,771	22,721	19,806	19,936	19,959
Shareholder's Equity	-17.5%	38,693	46,905	45,991	44,458	43,318	40,953	38,257	35,863	33,388	27,039	25,404	29,270	27,744	26,300	26,001	26,925	27,737	27,670	26,882	32,656	32,766
Retained Earnings	-12.6%	54,198	62,039	61,081	59,928	58,437	56,252	53,696	51,691	48,777	48,888	47,362	51,107	49,724	48,272	46,602	45,804	45,295	44,065	42,579	42,189	41,523
Additional Paid-In Capital	-0.6%	44,219	44,467	44,379	44,243	44,115	44,275	44,238	44,149	44,039	39,613	39,588	39,489	39,373	39,697	39,660	39,561	39,484	38,768	38,808	39,762	39,741
Accumulated Depreciation	1.0%	18,432	18,256	17,985	17,921	17,798	18,498	18,192	18,155	18,236	18,732	18,162	18,572	18,182	17,706	17,686	17,281	17,049	16,623	16,324	16,568	16,567
Minority Interest	-31.0%	49.00	71.00	67.00	66.00	75.00	70.00	73.00	69.00	94.00	94.00	87.00	84.00	102	95.00	94.00	87.00	102	131	181	234	237

Cashflow (Last 12 Months)
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Cashflow From Operations	-3.8%	15,075	15,673	19,095	19,760	18,955	16,643	13,122	11,437	8,222	8,150	7,617	4,445	7,089	8,255	8,884	12,238	10,805	11,103	10,922	11,349	7,385
Share Based Compensation	5.7%	598	566	541	515	493	488	479	472	481	470	441	437	412	402	388	392	382	361	348	341	326
Cashflow From Investing	-168.7%	-16,512	-6,146	-4,960	-15,261	-15,360	-16,908	-16,421	-9,069	-10,094	-8,251	-9,193	-5,159	-2,882	-4,525	-2,529	312	1,781	4,879	4,314	2,078	1,089
Cashflow From Financing	68.4%	-2,552	-8,087	-9,119	-2,358	-1,930	2,109	3,097	-738	-2,315	-3,440	-2,832	-6,215	-5,516	-8,737	-8,861	-12,416	-11,169	-12,052	-13,160	-13,379	-10,938
Dividend Payments	1.6%	7,235	7,120	7,012	6,905	6,807	6,710	6,610	6,509	6,405	6,309	6,215	6,078	5,927	5,818	5,695	5,567	5,458	5,301	5,172	5,178	5,176
Buy Backs	226.8%	487	149	-	18.00	601	840	840	822	239	-	1,281	2,331	3,736	4,971	4,780	9,663	9,254	9,615	9,091	4,860	4,023

MRK Income Statement

2023-06-30

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Sales	$ 15,035	$ 14,593	$ 29,522	$ 30,494
Costs, Expenses and Other
Cost of sales	4,024	4,216	7,951	9,596
Selling, general and administrative	2,702	2,512	5,182	4,834
Research and development	13,321	2,798	17,597	5,374
Restructuring costs	151	142	218	194
Other (income) expense, net	172	438	259	1,148
Total Costs, Expenses and Other	20,370	10,106	31,207	21,146
(Loss) Income Before Taxes	(5,335)	4,487	(1,685)	9,348
Income Tax Provision	637	538	1,462	1,092
Net (Loss) Income	(5,972)	3,949	(3,147)	8,256
Less: Net Income Attributable to Noncontrolling Interests	3	5	7	2
Net (Loss) Income Attributable to Merck & Co., Inc.	$ (5,975)	$ 3,944	$ (3,154)	$ 8,254
Basic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	$ (2.35)	$ 1.56	$ (1.24)	$ 3.26
(Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	$ (2.35)	$ 1.55	$ (1.24)	$ 3.25

MRK Balance Sheet

2023-06-30

CONDENSED CONSOLIDATED BALANCE SHEET - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 5,660	$ 12,694
Short-term investments	718	498
Accounts receivable (net of allowance for doubtful accounts of $86 in 2023 and $72 in 2022)	11,030	9,450
Inventories (excludes inventories of $3,220 in 2023 and $2,938 in 2022 classified in Other assets - see Note 7)	5,930	5,911
Other current assets	6,639	7,169
Total current assets	29,977	35,722
Investments	1,214	1,015
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,432 in 2023 and $17,985 in 2022	22,231	21,422
Goodwill	21,195	21,204
Other Intangibles, Net	19,665	20,269
Other Assets	10,187	9,528
Total Assets	104,469	109,160
Current Liabilities
Loans payable and current portion of long-term debt	2,839	1,946
Trade accounts payable	3,442	4,264
Accrued and other current liabilities	13,747	14,159
Income taxes payable	1,489	1,986
Dividends payable	1,877	1,884
Total current liabilities	23,394	24,239
Long-Term Debt	34,072	28,745
Deferred Income Taxes	996	1,795
Other Noncurrent Liabilities	7,265	8,323
Merck & Co., Inc. Stockholders’ Equity
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2023 and 2022	1,788	1,788
Other paid-in capital	44,219	44,379
Retained earnings	54,198	61,081
Accumulated other comprehensive loss	(4,900)	(4,768)
Stockholders' equity before deduction for treasury stock	95,305	102,480
Less treasury stock, at cost: 1,037,678,033 shares in 2023 and 1,039,269,638 shares in 2022	56,612	56,489
Total Merck & Co., Inc. stockholders’ equity	38,693	45,991
Noncontrolling Interests	49	67
Total equity	38,742	46,058
Liabilities and Equity	$ 104,469	$ 109,160

Merck & Co Inc Stock Research

Market Summary

MRK Alerts

MRK Stock Price

MRK RSI Chart

MRK Valuation

MRK Price/Sales (Trailing)

MRK Profitability

MRK Fundamentals

MRK Revenue

MRK Earnings

Price Action

52 Week Range

MRK Financial Health

MRK Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for MRK

Which funds bought or sold MRK recently?

Latest Funds Activity

MRK Alerts

Schedule 13G FIlings of Merck

Recent SEC filings of Merck

Peers (Alternatives to Merck)

Merck News

Returns for MRK

Cumulative Returns on MRK

Risks for MRK

What is the probability of a big loss on MRK?

How does MRK drawdown profile look like?

Financials for Merck

Income Statement (Last 12 Months)
(In Millions)

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Millions)

MRK Income Statement

MRK Balance Sheet

About Merck

Market Summary

MRK Alerts

MRK Stock Price

MRK RSI Chart

MRK Valuation

MRK Price/Sales (Trailing)

MRK Profitability

MRK Fundamentals

MRK Revenue

MRK Earnings

Price Action

52 Week Range

MRK Financial Health

MRK Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for MRK

Which funds bought or sold MRK recently?

Latest Funds Activity

MRK Alerts

Schedule 13G FIlings of Merck

Recent SEC filings of Merck

Peers (Alternatives to Merck)

Merck News

Returns for MRK

Cumulative Returns on MRK

Risks for MRK

What is the probability of a big loss on MRK?

How does MRK drawdown profile look like?

Financials for Merck

Income Statement (Last 12 Months).css-zgnqz2{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:0.75rem;line-height:1.66;letter-spacing:0.03333em;color:#595959;}(In Millions)

Balance Sheet(In Millions)

Cashflow (Last 12 Months)(In Millions)

MRK Income Statement

MRK Balance Sheet

About Merck

Income Statement (Last 12 Months)
(In Millions)

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Millions)